Dr Kopetz
Adam R et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): Results from a multicentre, open-label, prospective, randomised controlled trial. Lancet 2024;404(10458):1107-18. Abstract
André T et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): A randomised, open-label, phase 3 trial. Lancet 2025;405(10476):383-95. Abstract
Fakih M et al. Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC). ASCO 2024;Abstract LBA3510.
Kopetz S et al. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: A randomized phase 3 trial. Nat Med 2025;[Online ahead of print]. Abstract
Kopetz S et al. Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nat Med 2024;30(11):3261-71. Abstract
Lenz H-J et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. ASCO 2024;Abstract 3503.
Raghav K et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 2024;25(9):1147-62. Abstract
Siena S et al. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: Biomarker analyses of DESTINY-CRC01. Nat Commun 2024;15(1):10213. Abstract
Strickler JH et al. Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). ASCO 2024;Abstract 3509.
Yaeger R et al. Adagrasib (ada) + cetuximab (cetux) for KRASG12C-mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1. Gastrointestinal Cancers Symposium 2025;Abstract 131.
Dr Meyerhardt
Cercek A et al. Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. ASCO 2024;Abstract LBA3512.
Chalabi M et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N Engl J Med 2024;390(21):1949-58. Abstract
Chalabi M et al. Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2. ESMO 2024;Abstract LBA24.
Dasari A et al. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. ASCO 2023;Abstract 3522.
de Gooyer PG et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: A phase 2 trial. Nat Med 2024;30(11):3284-90. Abstract
Kataoka K et al. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol 2024;35(11):1015-25. Abstract
Lieu CH et al. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA). Gastrointestinal Cancers Symposium 2024;Abstract TPS243.
Martling A et al. Low-dose aspirin reduces recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from the ALASCCA trial. Gastrointestinal Cancers Symposium 2025;Abstract LBA125.
Nakamura Y et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 2024;30(11):3272-83. Abstract
Nowak J et al. Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. Gastrointestinal Cancers Symposium 2025;Abstract LBA14.
Shah P et al. Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort. Gastrointestinal Cancers Symposium 2025;Abstract 15.
Tie J et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial. ASCO 2024;Abstract 108.